Laronidase
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie
Trial Timeline
Oct 22, 2010 → Dec 21, 2022
NCT ID
NCT00418821About Laronidase
Laronidase is a approved stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is terminated. This product is registered under clinical trial identifier NCT00418821. Target conditions include Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05134571 | Approved | Completed |
| NCT00418821 | Approved | Terminated |
| NCT00144768 | Approved | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I